Ora to Showcase New Technologies and Research Findings at ARVO 2023
Stop by booth #1401 to see how the leader in ophthalmology research is
solving the biggest challenges in study enrollment
BOSTON--(BUSINESS WIRE)--#ARVO2023--Ora, Inc. supports eye care innovators across every phase of drug and device development to help bring their life-changing therapies to patients. Completely dedicated to ophthalmology and truly global, Ora’s value-driven team has helped partners achieve over 80 product approvals.
Trusted relationships, proven expertise and a passion to innovate and serve make Ora the partner of choice when it comes to delivering research programs with precision, scale, and speed. Novel technologies and operationally excellent systems and procedures continue to power Ora’s growth as the organization focuses on reshaping the future of research in ophthalmology.
“We love ARVO! It continues to be an essential showcase for Ora’s research and development efforts since we first attended in 1972. Now, over 50 years later, Ora continues to be inspired by the ARVO experience which feels like the global town square for translational research,” said Stuart B. Abelson, President, CEO and Chairman of Ora. “We are grateful for the opportunity to serve ophthalmology innovators and help them bring their drugs and devices forward through development to benefit patients around the world. Come visit us in New Orleans so we can share how Ora’s experienced people, proven processes, and innovative technologies can increase your chances of development success.”
Poster Presentation Schedule
Tuesday, April 25, 2023
Poster | Presenter | Time (CDT) | Poster # |
“Power and Sample Size Requirements for Early-to-Intermediate Dry AMD using a Novel Variable Contrast Flicker Sensitivity Test” | Dr. Gustavo De Moraes | 8:45 - 10:45AM | 2770 - C0057 |
“A novel computerized test for early to intermediate age-related macular degeneration: the Ora contrast sensitivity test (Ora CST)” | Dr. John Rodriguez | 2771 - C0058 | |
“Olopatadine Hydrochloride Ophthalmic Solution 0.7% is Superior to Fluticasone Propionate Nasal Spray 50 mcg or Loratadine in Preventing Signs and Symptoms of Allergic Conjunctivitis using an Allergen Challenge Model” | Paul Gomes | 3:30 - 5:15PM | 3563 - B0405 |
Wednesday, April 26, 2023
Poster | Presenter | Time (CDT) | Poster # |
“Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease (DED) including a Subpopulation of Hyper-Responders to CAE® Challenge: Results from 2 Independent Clinical Trials” | George Ousler | 10:30 - 12:30PM | 3969 - B0286 |
“Dry Eye Redness: Ora Auto Redness & Auto Horizontality Algorithms Evaluated Against Expert Human Graders” | Ben Liu |
3988 - B0305
| |
“Potential Clinical Benefits of a Composite Automated Score for Dry Eye Redness” | Rachel Zilinskas (presented by Adam Ham) | 3987 - B0304 | |
“Correlation of variation in airflow in the CAE chamber to patient inter-palpebral fissure height and blink rate” | Dr. Ethan Bensinger | 3947 - B0264 |
Ora at ARVO 2023 (Booth #1401)
Experience how over forty years of ophthalmic innovation is shaping the future of clinical development. With a global research community designed to optimize site preparedness, study execution, and global data, Ora’s systems and programs provide unparalleled support and expanded feasibility. Experience interactive product demos and sit in on presentations from our subject matter experts to discover how Ora sets the standard for global product development.
About Ora, Inc.
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 82 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn.
Ora® and Ora Logo are registered trademarks of Ora, Inc.
Contacts
Media
Claire Russell
crussell@oraclinical.com
+1 (919) 597-9029
Editor Details
-
Company:
- Businesswire
